NDRC fines Medtronic for price monopoly

0
1662
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

The National Development and Reform Commission’s (NDRC) recent administrative penalty against Medtronic (Shanghai) management for the company’s price monopoly signalled a new focus of antitrust enforcement, said a legal expert.

“The targets of the NDRC’s antitrust investigations have been rolled over one after another, and the medical device and drug sectors are the next major target industries,” Alan Zhou, a partner of Global Law Office in Shanghai, told China Business Law Journal. “Vertical monopoly agreement fixing resale price and limiting minimum resale price is the major focus in NDRC’s investigation”.

Story_3This has been the first decision published by the NDRC among a series of antitrust investigations regarding medical devices and medical enterprises since late 2016. Medtronic’s execution and implementation of monopoly agreement fixing and limiting minimum resale prices was found to have violated the Antitrust Law. Accordingly, the NDRC ordered Medtronic to immediately cease the implementation of its monopoly agreements and imposed a fine of RMB118.5 million (US$17 million).

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link